Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study
Ara H Dikranian, Rubaiya Mallay, Mike Marshall, Megan Francis-Sedlak, Robert J Holt, Ara H Dikranian, Rubaiya Mallay, Mike Marshall, Megan Francis-Sedlak, Robert J Holt
Abstract
Introduction: Rheumatoid arthritis (RA) produces debilitating morning stiffness. Exogenous glucocorticoids can help with these symptoms when timed appropriately. Bedtime dosing of delayed-release prednisone (DR-prednisone) matches the rise of inflammatory cytokines before awakening and can improve stiffness and other RA symptoms. A prospective open-label study was conducted in patients currently on stable doses of immediate-release prednisone (IR-prednisone) who were switched to DR-prednisone to analyze the incremental benefit of better timed and lower dose glucocorticoid therapy.
Methods: Twelve US sites enrolled patients with moderate-severe RA into a 12-week prospective study. Patients were switched from IR- to DR-prednisone while maintaining other existing background therapies. Change from baseline in morning stiffness severity, morning stiffness duration, swollen and tender joint counts (S-TJC), 28 joint disease activity score (DAS28), and patient/physician global assessment (PGA/PhGA), among others, were measured. Post-hoc analyses were performed on those completing 10 weeks of treatment and those with >60 min of morning stiffness at baseline.
Results: Fifty-six patients had at least one follow-up visit and were similar in demographics to previous controlled trials with DR-prednisone with regard to baseline age and DAS28-CRP but had lower morning stiffness and RA duration. DR-prednisone produced a trend toward lower morning stiffness severity and duration with a reduction in daily prednisone dose of almost 1 mg. Patients treated with DR-prednisone for ≥10 weeks demonstrated significant reductions in morning stiffness duration, SJC, TJC, DAS28-CRP, and PhGA (all p ≤ 0.04). Patients treated for ≥10 weeks with >60 min of baseline morning stiffness produced similar results in these measures as well as a 21% reduction in morning stiffness severity (p = 0.02).
Conclusion: Patients switched to DR-prednisone from IR-prednisone in this practice-based study maintained or improved their outcomes across a variety of domains, and results were comparable to previous controlled trials in which patients completed at least 10 weeks of treatment.
Funding: Horizon Pharma USA, Inc.
Trial registration: ClinicalTrials.gov identifier, NCT02287610.
Keywords: Circadian; Glucocorticoids; Morning stiffness; Outcome assessment; Prednisone; Rheumatoid arthritis.
Figures
References
- Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther. 2009;11:249. doi: 10.1186/ar2758.
- Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156:329–339. doi: 10.7326/0003-4819-156-5-201203060-00004.
- Cutolo M, Seriolo B, Craviotto C, et al. Circadian rhythms in RA. Ann Rheum Dis. 2003;62:593–596. doi: 10.1136/ard.62.7.593.
- Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open. 2016;2:e000203. doi: 10.1136/rmdopen-2015-000203.
- Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) Ann Rheum Dis. 2013;72:204–210. doi: 10.1136/annrheumdis-2011-201067.
- Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371:205–214. doi: 10.1016/S0140-6736(08)60132-4.
- Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010;69:1275–1280. doi: 10.1136/ard.2009.126888.
- Alten R, Holt R, Grahn A, et al. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone. Scand J Rheumatol. 2015;44:354–358. doi: 10.3109/03009742.2015.1038582.
- Buttgereit F, Kent JD, Holt RJ, et al. Improvement thresholds for morning stiffness duration in patients receiving delayed- versus immediate-release prednisone for rheumatoid arthritis. Bull Hosp Jt Dis 2013. 2015;73:168–177.
- da Silva JA, Phillips S, Buttgereit F. Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scand J Rheumatol Suppl. 2011;125:6–11. doi: 10.3109/03009742.2011.566434.
- Cutolo M, Hopp M, Liebscher S, et al. Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. RMD Open. 2017;3:e000426. doi: 10.1136/rmdopen-2016-000426.
- Zakout SA, Lynsey LC, Jessop D, et al. Circadian variation in plasma IL-6 and the role of modified-release prednisone in polymyalgia rheumatica. Int J Clin Rheumatol. 2014;9:431–439. doi: 10.2217/ijr.14.29.
- Aletaha D, Funovits J, Ward MM, et al. Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. Arthritis Rheum. 2009;61:313–320. doi: 10.1002/art.24282.
- Boers M, Buttgereit F, Saag K, et al. What is the relationship between morning symptoms and measures of disease activity in patients with rheumatoid arthritis? Arthritis Care Res. 2015;67:1202–1209. doi: 10.1002/acr.22592.
- Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol. 2007;34:696–705.
- Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764–770. doi: 10.7326/0003-4819-141-10-200411160-00007.
- Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–293. doi: 10.1136/ard.2005.038638.
- Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119–1124. doi: 10.1136/ard.2008.092163.
- Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333:142–146. doi: 10.1056/NEJM199507203330302.
- van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1–12. doi: 10.7326/0003-4819-136-1-200201010-00006.
- Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:3371–3380. doi: 10.1002/art.21421.
- Cutolo M, Iaccarino L, Doria A, et al. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol. 2013;31:498–505.
Source: PubMed